Opinion|Videos|June 27, 2024
Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series
- What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
- What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options?
Advertisement
Related to this article
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
Iberdomide Regimen Cuts RRMM Progression Risk by 51%, Trial Finds
5